

Recombinant Technology

Functional human monoclonal antibodies of all isotypes constructed from phage display library-derived single-chain Fv antibody fragments

Edwin Boel^{a,*}, Sjors Verlaan^b, Miriam J.J.G. Poppelier^a, Nomdo A.C. Westerdal^b,
Jos A.G. Van Strijp^a, Ton Logtenberg^b

^a*Eijkman-Winkler Institute for Microbiology, Infectious Diseases and Inflammation, Utrecht University Hospital, Rm G04.614,
P.O. Box 85500, NL-3508 GA Utrecht, The Netherlands*

^b*Department of Immunology, Utrecht University Hospital, Utrecht, The Netherlands*

Received 27 August 1999; received in revised form 16 February 2000; accepted 16 February 2000

Abstract

We have constructed a series of eukaryotic expression vectors that permit the rapid conversion of single chain (sc) Fv antibody fragments, derived from semi-synthetic phage display libraries, into intact fully human monoclonal antibodies (mAb) of each isotype. As a model, a scFv fragment specific for sheep red blood cells (SRBC) was isolated from a semi-synthetic phage antibody (Ab) display library, and used to produce human mAbs of IgM, IgG1–IgG4, IgA1, IgA2m(1) and IgE isotype in vitro in stably transfected cells. N-terminal protein sequence analysis of purified immunoglobulin heavy (H) and light (L) chains revealed precise proteolytic removal of the leader peptide. Biochemical analysis of purified recombinant human mAbs demonstrated that properly glycosylated molecules of the correct molecular size were produced. The IgG and IgA mAbs retained SRBC-binding activity, interacted with different Fc receptor-transfectants, and induced complement-mediated hemolysis and Ab-dependent phagocytosis of SRBC by neutrophils in a pattern consistent with the immunoglobulin (Ig) H chain isotype. We conclude that in vitro produced recombinant human mAbs constructed from phage display library-derived scFv fragments mirror their natural counterparts and may represent a source of mAbs for use in human therapy. © 2000 Elsevier Science B.V. All rights reserved.

Keywords: Isotype switching; Phagocytosis; Complement-mediated lysis; Cloning vectors; Transient and stable expression

Abbreviations: Ab, antibody; BHK, baby hamster kidney cells; C, constant; complement; ELISA, enzyme-linked immunosorbent assay; FITC, fluorescein isothiocyanate; HRP, horseradish peroxidase; H, immunoglobulin heavy chain; Ig, immunoglobulin; L, immunoglobulin light chain; mAb, monoclonal antibody; NHS, normal human serum; scFv, single-chain Fv fragment; SRBC, sheep red blood cell; V, variable; V_H, immunoglobulin heavy chain variable region; V_L, immunoglobulin light chain variable region

*Corresponding author. Tel.: +31-30-2507-625; fax: +31-302541-770.

E-mail address: eboel@wxs.nl (E. Boel)

1. Introduction

Since the advent of hybridoma technology, the potential of murine mAbs for therapeutic application in humans has been a focus of interest.

Clinical testing has shown that murine antibodies may evoke an anti-mouse immune response, the occurrence and magnitude of which is likely affected by the disease-related immune status of the recipient

and by the mode and duration of antibody administration (Jaffers et al., 1986). Although mouse antibodies of various isotypes, compared to their human equivalents, less efficiently bind human complement and Fc receptors expressed by human effector cells, some mouse antibodies have been shown to be cytotoxic in humans (Bonnefoy-Berard and Revillard, 1996). Yet, it may be anticipated that antibodies with human Fc regions are more effective cytotoxic reagents in human immunotherapy.

Attempts to generate mAbs of human origin using a variety of methods including somatic hybridization or immortalization of cells with Epstein–Barr virus have met with considerable technological and ethical problems and have not resulted in the establishment of reliable and robust methods. Humanization of murine mAbs by replacing Ig constant (C) or variable (V) region sequences, resulting in ‘chimeric’ and ‘humanized’ Abs (Morrison et al., 1984; Jones et al., 1986), has led to a reduction of the immunogenicity of the molecules. Further reduction of immunogenicity can be expected from completely human mAbs, which have recently been derived from transgenic mice and from phage display libraries.

Immunization of transgenic mice harboring human Ig H and L chain mini-loci and subsequent immortalization of spleen cells by somatic hybridization yields high-affinity human mAbs of predefined specificities (Taylor et al., 1992; Mendez et al., 1997). An alternative approach has been the construction of libraries of human Ab fragments expressed on the surface of filamentous phages and the selection of desired Ab-specificities by in vitro panning (Burton and Barbas, 1994; Winter et al., 1994). The Ab fragments obtained from these libraries are small scFv or Fab fragments and differ from intact natural Abs in terms of valency, pharmacokinetic behavior, and ability to recruit Fc region-dependent effector functions.

We have previously described the construction of a semi-synthetic phage Ab display library of scFv fragments and shown that a variety of phage selection procedures on purified antigens, tissue fragments, microorganisms, and eukaryotic cells permit the isolation of specific scFv Ab fragments (de Kruif et al., 1995a,b, 1996; Boel et al., 1998). Here we describe the construction of eukaryotic expression

vectors for the rapid conversion of phage display library-derived scFv Ab fragments to intact human IgG1, IgG2, IgG3, IgG4, IgA1, IgA2m(1), IgM, and IgE Abs. The procedure involves two cloning steps and constructs can be transiently or stably expressed in eukaryotic cells. The combined experiments indicate that the in vitro produced Abs are correctly assembled and glycosylated. Intact human mAbs constructed from a phage display library-derived scFv specific for SRBC were shown to perform effector functions that correlated with their C region isotype.

2. Materials and methods

2.1. Construction of expression vectors

pBR322 plasmids containing the human κ L chain (Hieter et al., 1982) or H chain IgG1-4 C regions (C γ 1-4) (Kirsch et al., 1982) were used as a template to append *Bam*HI, *Not*I and *Sma*I restriction sites to the C regions by PCR amplification (Table 1A,B). The amplified products were cloned into the pNUT expression vector (Palmiter et al., 1987) using *Bam*HI and *Sma*I restriction enzymes, resulting in the plasmids pNUT-C κ and pNUT-C γ 1–4. Because the C γ 1–3 C regions contain an internal *Sma*I restriction site, the amplified products were first digested with *Bam*HI and subsequently partially digested with *Sma*I, subjected to agarose gel electrophoresis and the full-length products were isolated and cloned into the pNUT vector.

The C regions of human IgM (C μ) and IgA1 and IgA2m(1) (C α 1 and C α 2) (Ravetch et al., 1980) were PCR amplified from genomic clones in plasmid pBR322 using C μ - and C α -specific primers, respectively (Table 1A,B), digested with *Bam*HI and *Eco*RV and cloned into the *Bam*HI- and *Sma*I-digested pNUT vector.

A *Bam*HI restriction fragment containing the human IgE C region gene (C ϵ) was obtained from a λ charon 38A phage clone (Max et al., 1982) and subcloned into the pBluescript vector (van der Stoep, 1995). C ϵ was PCR amplified from this plasmid with the C ϵ primers introducing *Not*I and *Eco*RV restriction sites (Table 1A,B), and cloned into the pNUT-

Table 1
Oligonucleotide primers^a

(A) Human back primers for immunoglobulin constant regions	
C _κ -5	TTTATTAAGGGATCCGCGGCCGCTAGGAAGAACTCAAAAC
C _γ -5	CAGGTGCGGATCCAGCGGCCGCGAGCCCAGACACTGGAC
C _μ -5	CAGCCCTGGGATCCAGGGCACGCGGCCGCGAGCTCCTCAC
C _α -5	CAATCATAAGGATCCTCACGCGGCCGCTCTGTGCTGGGTTCT
C _ε -5	CAGGCTGGCGGCCGCTGGCCTGAG
(B) Human forward primers for immunoglobulin constant regions	
C _κ -3	TGGGGGCCCCGGGTACCTCTAACACTCTCCCT
C _γ -3	GGGGCTTCCCGGTACCGCACTCATTTACCCGGAGA
C _μ -3	CCGAGCCTGATATCAGGGTACCAGGGTCAGTAG
C _α -3	CAATATCGGATATCAGGTACCTCAGTAGCAGGTGCCGAC
C _ε -3	AGGGAGGGGATATCAGGTACCTCATTTACC
(C) Primers to generate the HAVT20 leader	
HAVT20	CCCATAGAGGAATTCCGGATCCAATGGCATGCCCTGGCTTCCTGTGGGCACCTTGATCTCCACCTGTCTTGAATTTCCA
	TGGCTGAAATTGAGCTCGTCGACAGGTGAGTGCGGCCGC
	AAGCTTAAAGGTCTGG
HAVT20-C	CCAGACCTTTAAGCTTGCGG
(D) Human V _κ back primers	
V _κ 1a	TGTGACATCGAGCTCACCCAGTCTCCATCC
V _κ 2a	TGTGATGTTGAGCTCACTCAGTCTCCACTC
V _κ 3pan	GA(A/T/C)AT(T/C)GAGCTCAC(G/A/T/C)CAGTCTCC
V _κ 4	TGTGACATCGAGCTCACCCAGTCTCCAGACTCC
(E) Human J _κ forward primer	
J _κ pan	TTCTCGACTTGCGGCCGCAAAGTGCACCTACGTTTGATCTCCACCTTG
(F) Human V _λ back primers	
V _λ 1	TCCCAGTCTGAGCTCACGCAGCCGCCCTC
V _λ 2	TCCCACGTTGAGCTCACTCAACCGCCCTCTG
V _λ 3a	TCCTCCTATGAGCTCACTCACCCACCT
V _λ 3b	TCCTCCTATGAGCTCACTCAGGACCT
(G) Human J _λ forward primer	
J _λ pan	TTCTCGACTTGCGGCCGCGACTCACCTAGGACGGTCAGCTTGCTC

^a Restriction sites used for cloning are underlined.

γ4 vector from which the γ4 chain was removed by restriction digestion with *NotI* and *SmaI*.

The pLEADER vector was constructed by extension of two partially complementary oligonucleotides, HAVT20 and HAVT20C (Table 1C), and cloning of the double-stranded product into the pUC18 vector using *EcoRI* and *HindIII*.

The seven V_L genes used previously to construct the phage display library of scFv fragments (de Kruif et al., 1995a), were PCR amplified with the relevant primers (Table 1D–G) to introduce *SacI* and *NotI*

restriction sites and a splice donor site, and cloned into the pLEADER vector (Figs. 1A and 2). The V_L gene fused to the HAVT20 leader was subsequently cloned into the pNUT-C_κ vector using *BamHI* and *NotI*.

The phagemid containing the coding sequence for the anti-SRBC scFv S6 was isolated from *Escherichia coli* XL1-blue cells (Stratagene, La Jolla, CA) and purified using a Qiagen plasmid isolation kit (Qiagen, Hilden, Germany). The phagemid was digested with *NcoI* and *XhoI* and the V_H region




Fig. 1. Expression vectors for human Ig H and L chains and strategy for converting scFv fragments into intact human mAbs. (A) The *V_L* region is PCR-amplified to introduce restriction sites and a splice donor sequence (D) and cloned into the pLEADER vector. The *V_L* region fused to the HAVT20 leader sequences is excised and subcloned into the pNUT-C_k vector. (B) The *V_H* region is excised from the pHEN1 phagemid, cloned into pLEADER, and subcloned together with the HAVT20 leader and splice donor sequence into pNUT containing the different H chain C regions. Amp, ampicillin resistance gene; DHFR, dihydrofolate synthetase gene; gIII, M13 minor coat protein III gene; Mtp, human metallothionein promoter; SV40, SV40 origin of replication.




Fig. 2. The cloning sites of pLEADER. Restriction endonuclease sites are underlined, the HAVT20 leader and the first four amino acids of the VI chain are indicated.

cloned into the *NcoI*- and *SalI*-digested pLEADER vector (Fig. 2). Subsequently, the HAVT20 leader and V_H were subcloned into the pNUT expression vectors using *BamHI* and *NotI* restriction sites (Fig. 1B).

2.2. Phage selection

Phage Ab S6 specific for SRBC was isolated from a semi-synthetic phage display library as described previously (de Kruif et al., 1995a). Approximately 5×10^{12} phages were blocked in 2% low-fat dry milk powder in PBS and subsequently mixed with 10^5 SRBC. The phages were allowed to bind for 3 h at 4°C, after which the SRBC were washed five times in PBS by pelleting the SRBC and removing the supernatant containing non-binding phages. After the final washing step the pelleted SRBC were resuspended in water and binding phages were used to infect *E. coli* XL1-Blue cells. The *E. coli* cells were plated on agar containing the appropriate antibiotics and 5% glucose, and used to prepare phages for a subsequent round of selection as previously described (Marks et al., 1991). After three rounds of selection, monoclonal phage preparations were tested for SRBC-binding by flow cytometric analysis on a FACScan (Becton-Dickinson, San Jose, CA) as described (de Kruif et al., 1995b).

2.3. Transfection of COS cells

SV40-transformed African green monkey kidney cells (COS-7) cells were maintained in DMEM with

10% FCS at 37°C in a 5% CO₂ humidified chamber. Cells were washed in PBS and transfected with the plasmids in RPMI 1640 medium containing 2% FCS, 100 µM chloroquine and 400 µg/ml DEAE-dextran for 1.5 h, washed with PBS and supplemented with DMEM–10% FCS. After transfection, the cells were cultured for 3–5 days before the expression of Abs was determined in the supernatant by ELISA.

2.4. Transfection of fur-BHK cells

Baby hamster kidney 21 (BHK-21) cells containing the furin gene (Lankhof, 1996) were transfected using the calcium–phosphate method as described (Graham and van der Eb, 1973). Selection was initiated by adding 100 µM of methotrexate (Sigma, St. Louis, MO, USA). After 2 weeks, colonies of resistant cells were picked and cultured in methotrexate-containing medium. The production of Abs was determined in the supernatant by ELISA.

2.5. ELISA

All Abs used for ELISA were from Southern Biotechnology Associates (Birmingham, AL), except the IgG subclass-specific Abs, which were from the Central Laboratory for Bloodtransfusion (Amsterdam, The Netherlands). Wells of a 96-well plate (Flow Laboratories, Irvine, UK) were coated with a 1/1000 dilution of a goat anti-human κ L chain Ab in PBS overnight at 4°C and 100-µl aliquots of culture supernatant or purified Abs were added. Plates were incubated at 37°C for 1 h, washed in 0.05% Tween

20–PBS, and a 1/1000 dilution of horseradish peroxidase (HRP)-labeled Ab specific for the relevant human isotype was added. The plates were incubated for 1 h at 37°C and washed with Tween 20–PBS. HRP activity was quantified by addition of tetramethylbenzidine free base substrate and further incubation for 10 min at room temperature. The enzyme reaction was stopped with H₂SO₄ and the OD₄₅₀ was determined.

2.6. Purification of human Abs

The transfected cell lines were cultured in serum-free CHO-S-SFM II medium (Gibco-BRL, Grand Island, NY) and culture supernatants were harvested twice weekly. Cellular debris was removed from all supernatants by centrifugation at 3000 rpm for 10 min followed by filtration over a 0.2-μm membrane (Gelman Sciences, Ann Arbor, MI).

All Ig subclasses were purified from culture medium by protein A–Sephacryl chromatography (Pharmacia, Uppsala, Sweden). For every purification a new column was used to avoid cross-contamination of different Abs. The concentration of purified mAbs was determined using radial immunodiffusion plates

of the relevant isotype (LC-Partigen; Behringwerke, Marburg, Germany) according to the manufacturer's recommendations.

2.7. SDS–PAGE and N-terminal amino acid sequence analysis

Aliquots of the purified Abs containing 3 μg of protein were run on a 10% reducing or 7.5% non-reducing SDS–polyacrylamide gel. Proteins were detected by Coomassie brilliant blue staining. For N-terminal amino acid sequence analysis, proteins were blotted onto a Problott membrane (Applied Biosystems, Foster City, CA) using 10 mM CAPS–10% methanol as blotting buffer. H and L chains were detected by Coomassie brilliant blue staining, and sequenced by Edman degradation.

2.8. Glycosylation analysis

Glycosylation of recombinant human Abs was determined following the same procedure as described for the isotype-specific ELISA, except that

FITC-labeled lectins were used in the detection step. After washing, individual wells were filled with PBS and bound FITC was quantified using a fluorescence multi-well reader (Cytofluor; Perspective Biosystems, Framingham, MA). The following lectins were used: *Limax flavus* (LFA) for the detection of sialic acid, *Erythrina cristagalli* (ECA) for galactose(β1,4)*N*-acetylglucosamine, and *Canavalia ensiformis* (Con A) for α-D-mannose, α-D-glucose, branched mannose (EY Laboratories, San Mateo, CA).

2.9. Binding of human Abs

SRBC were sensitized with the different purified S6 Ab preparations by incubation for 30 min at 37°C under agitation and washed in RPMI 1640 medium containing 5% FCS. SRBC-bound S6 mAbs were detected with FITC-labeled Abs specific for human IgG or IgA (Southern Biotechnology Associates) by incubation for an additional hour at 37°C, followed by flow cytometric analysis on a FACScan.

2.10. Fc receptor-transfected cell lines and SRBC–Ig rosetting assay

Murine B cell line IIA1.6 transfected with FcγRI (van Vugt et al., 1996), FcγRIIa-H131, FcγRIIa-R131 (van den Herik-Oudijk et al., 1994), FcγRIIb-NA2 (Ory et al., 1991) and FcαRI (Morton et al., 1995) were cultured in RPMI 1640, supplemented with 10% FCS, 100 units/ml penicillin, 100 μg/ml streptomycin, 2 mM glutamine, and 1 mM sodium pyruvate. Rosette formation between Fc receptor-transfected cell lines and Ab-sensitized SRBC was performed as described in detail elsewhere (van de Winkel et al., 1987).

2.11. Fluorescent labeling of SRBC and phagocytosis

SRBC were stained with the red fluorescent dye PKH26 (Sigma) as described in detail elsewhere (Van Amersfoort and Van Strijp, 1994). Heparinized blood was obtained from healthy volunteers and neutrophils were isolated as described previously (Troelstra et al., 1997).

PKH26-labeled SRBC were sensitized with the

different S6-Ab preparations by incubation at 37°C for 30 min under mild agitation. Neutrophils and sensitized SRBC were washed and resuspended in RPMI 1640 containing 1% BSA to a final concentration of 1×10^7 and 1.2×10^8 cells/ml, respectively. Twenty- μ l aliquots of neutrophils and SRBC were mixed, centrifuged at $25 \times g$ for 5 min at 4°C, incubated at 37°C for 20 min, washed and resuspended in 150 μ l PBS. Flow cytometric analysis was performed on a FACScan. Neutrophils were differentiated from free SRBC on the basis of their forward and side scatter properties.

2.12. Complement-mediated hemolysis

Complement-mediated hemolysis (CH50) was estimated by hemolytic microtiter assay as described previously (Klerx et al., 1983). To reduce background, NHS was preabsorbed with SRBC by mixing one volume of serum with three volumes of packed SRBC. After incubation for 20 min on ice, SRBC were removed by centrifugation and serum was stored in small aliquots at -70°C .

3. Results

3.1. Construction of vectors for the production of human IgG1-4, IgA1-2, IgM, and IgE mAbs

We have constructed a series of vectors that allow the rapid conversion of scFv Ab fragments isolated from a semi-synthetic phage display library, to complete human mAbs of every isotype. The previously described phage Ab display library of scFv fragments was constructed from seven different V_L genes and more than 10^8 V_H genes (de Kruif et al., 1995a). The V_H gene encoding a scFv isolated from this library was first cloned into the pLEADER vector, resulting in the introduction of a splice donor sequence at the 3' end and the eukaryotic HAVT20 leader peptide sequence at the 5' end of the V_H segment (Kimura et al., 1987; Kabat et al., 1991). The T cell receptor leader peptide HAVT20 was selected because it allowed the introduction of a *NcoI* restriction site at precisely the same position as was used in the pelB leader of the phage display library, without altering the amino acid sequence

(Hoogenboom et al., 1991). Part of the genomic human J_H4 mini gene sequence (Kabat et al., 1991) was introduced downstream of a *SalI* restriction site in the pLEADER vector, to complete the V_H region and to introduce a splice donor sequence. The V_H region was subcloned into pLEADER using *NcoI* and *XhoI*, the same restriction sites which were used to construct the library (de Kruif et al., 1995a). Subsequently, using the *BamHI* and *NotI* restriction sites, the HAVT20- V_H -splice donor construct was subcloned into the different expression vectors harboring the genomic H chain C regions, in which splice acceptor sequences are present (Fig. 1B).

The seven V_L genes present in the phage display library were PCR-amplified with primers introducing a splice donor site and restriction sites for cloning. To facilitate the cloning of V_L genes, the HAVT20 leader sequence is followed in frame by the sequence for the first four amino acids of a V_L domain containing a *SacI* restriction site, identical to that used in the construction of the phage display library (de Kruif et al., 1995a). The 3'-primer completes the V_L genes and adds part of the intron containing the splice donor sequence, and a restriction site. All V_L constructs were cloned into the pNUT-C κ vector (Fig. 1A). Thus, all L chains will contain a human κ C region.

The expression vectors are derivatives of pNUT, which contains a dihydrofolate reductase gene for selection of stably transfected cells and a SV40 origin of replication for transient expression in COS cells (Fig. 1).

3.2. Selection of SRBC-binding phage

Phages were selected for binding to SRBC, and after three rounds of selection monoclonal phage preparations were tested by flow cytometry. Clone S6 was specific for SRBC and did not bind to ox or human erythrocytes or sheep leukocytes (not shown). The V_H3 H chain and V_L3 L chain genes encoding scFv fragment S6 were cloned into the different expression vectors.

3.3. Expression and purification of recombinant mAbs

Integrity of the constructs was assessed by tran-

sient expression in COS cells. Supernatants were harvested 3–5 days after transfection and analysed by ELISA for the presence of Abs, and by flow cytometry for binding to SRBC (not shown). After construct integrity was confirmed, stably transfected cell lines were established by co-transfection of H and L chain constructs in fur-BHK21 cells. Fur-BHK21 cells contain the furin gene and have been shown to be superior in the production of complex, high-molecular weight proteins such as factor VIII protein (Lankhof, 1996).

Methotrexate-resistant clones were analysed for Ab production and stable cell lines were propagated in selection medium. Culture supernatant was harvested twice weekly and all subclasses were purified from pooled supernatants using a protein A column, based on the observation that protein A binds to human V_H3-encoded Ab domains (Sasano et al., 1993). MAb yields after purification as measured by radial gel filtration ranged from 5 to 18 mg/l of culture supernatant for the IgG subclasses, 0.5 to 3 mg/l for the IgA subclasses, 70 µg/l for IgM and 9.6 µg/l for IgE (Table 2). Because of their low yield, the IgM and IgE mAbs were not included in the functional studies.

3.4. Characterization of recombinant human S6 mAbs

All S6 mAbs produced were tested in ELISA for the presence of a κ L chain and for the isotype of the H chain. IgG1–4 subclass identity was confirmed using subclass-specific mAbs (not shown).

SDS–PAGE under reducing conditions showed H and L chain bands of the predicted size; L chains displayed a band of 30 kDa molecular mass while H chains revealed bands ranging from 50 to 60 kDa molecular mass, dependent on the isotype (Fig. 3A).

SDS–PAGE under nonreducing conditions revealed a single band of approximately 150–160 kDa, corresponding to the size of monomeric IgG mole-




Fig. 3. Coomassie brilliant blue-stained SDS–PAGE gel of the purified S6 Ab preparations under reducing (A) and nonreducing conditions (B). HH and LL indicate homodimers of H and L chains, respectively, of IgA2m(1). Lane 1, IgG1; lane 2, IgG2; lane 3, IgG3; lane 4, IgG4; lane 5, IgA1; lane 6, IgA2m(1); M, molecular weight marker.

cules (Fig. 3B). In purified IgA1 preparations, a predominant band of 160 kDa was observed. In addition, a band of approximately 120 kDa molecular mass was visible, probably representing a complex of a single H and L chain, as has been reported previously (Morton et al., 1993). Some high-molecular weight aggregates were noticeable near the top of the gel. A faint band of 80–90 kDa, representing less than 10% of the total protein content, most probably represents a partial degradation product. Similar bands of 60 and 80 kDa were noticed in the IgG3 and IgG4 preparations, respectively.

Under nonreducing conditions, SDS–PAGE of purified IgA2m(1) preparations revealed two predominant bands of 120 and 50 kDa molecular mass,

Table 2
Production levels of human immunoglobulins^a

IgG1	IgG2	IgG3	IgG4	IgA1	IgA2	IgM	IgE
17.9 mg	6.4 mg	13.3 mg	5.5 mg	3.0 mg	0.5 mg	70 µg	9.6 µg

^a Yield per liter after purification.

with some higher molecular weight aggregates. The 120 and 50 kDa bands represent disulfide-bonded H and L chain homodimers, respectively (Morton et al., 1993). In the IgA2m(1) allotype expressed here, H and L chain are not disulfide-linked. Instead, disulfide bonds are formed between the L chains (Mestecky and Kilian, 1985).

To verify the correct proteolytic removal of the HAVT20 leader peptide from the H and L chains, the N-terminal sequence of both chains from the S6-IgG4 Ab was determined. The amino acid sequences were precisely as predicted from the nucleotide sequences of the correctly cleaved V_H and V_L chains, EVQLVE and EIELT, respectively.

Human Ab molecules contain N-linked carbohydrates at conserved positions in the C regions of the H chains. Oligosaccharide is attached as high-mannose sugar and trimmed when the glycoprotein passes through the endoplasmic reticulum and the *cis* Golgi. Processing may cease at this point, yielding glycoproteins with high-mannose sugars attached. Alternatively, processing may proceed to a complex biantennary form. The lectin Con A was used to confirm glycosylation, while the lectins ECA and LFA were used to detect the two terminal sugar residues of fully processed carbohydrates, galactose and sialic acid, respectively. S6-IgG1 and S6-IgG2 were analyzed using FITC-labeled lectins, and binding was quantified on a fluorometer. Protein A-purified IgG1 and IgG2 mAbs or crude culture supernatants from fur-BHK21 cell lines transfected with the S6-IgG1 or S6-IgG2 constructs were captured on microwells coated with anti- κ L chain mAbs. Protein A-purified IgG1 and IgG2 mAbs displayed Con A reactivity, but lacked reactivity with ECA or LFA (not shown). In contrast, non-purified IgG1 and IgG2 present in culture supernatants bound Con A, ECA and LFA (not shown).

3.5. *In vitro* produced recombinant human mAbs are functional

The binding capacity of the different S6-Ab preparations was assessed by flow cytometry. The four human IgG and the two IgA isotypes revealed a similar pattern of binding to SRBC (Fig. 4). A control human IgG2 mAb, constructed from a phage library-derived scFv specific for group B streptococ-




Fig. 4. Binding of IgG and IgA mAbs to SRBC. SRBC were sensitized with serially diluted preparations of the different mAbs and binding was detected with relevant FITC-labeled Abs by flow cytometry. Human mAb GBS7-IgG2, specific for group B streptococcal type III capsular polysaccharide, served as a control for background staining.

cal type III capsular polysaccharide (GBS7-IgG2, de Kruif et al., 1995a) and produced and purified as described for the S6 mAbs, did not reveal any binding with SRBC (Fig. 4).

The interaction of recombinant S6 Ab with a panel of Fc receptor-transfected cell lines was determined using a SRBC-rosetting assay (Table 3). IgG1 and IgG3 were bound by all Fc γ receptors, while IgG2-opsonized SRBC only formed rosettes with the Fc γ RIIa-H131 transfected cell line. IgG4 was efficiently bound by Fc γ RI, while some rosetting was observed with Fc γ RIIa. IgA1 and IgA2 were the only isotypes bound by the Fc α RI-transfected cell line.

The capacity to mediate phagocytosis of SRBC by neutrophils was determined for the IgG1 and IgG4 anti-SRBC mAbs (Fig. 5). Neutrophils readily

Table 3
Rosetting of Ig-opsonized SRBC with Fc receptor-transfected cells^a

	IgG1	IgG2	IgG3	IgG4	IgA1	IgA2
FcγRI	100/100	0	100/100	100/100	0	0
FcγRIIa-H131	76/77	58/21	70/83	19/6	0	0
FcγRIIa-R131	80/85	0	100/60	47/6	0	0
FcγRIIb-NA2	62/65	0	41/27	0	0	0
FcαRI	0	0	0	0	85/78	21/7

^a Rosetting was defined as at least three SRBC bound to a cell. Two hundred cells per sample were scored and percentages are depicted for SRBC sensitized with 0.6/0.3 μg/ml antibody.

phagocytosed IgG1-opsonized SRBC, while SRBC incubated with IgG4 were not phagocytosed. For comparison fluorescence of neutrophils incubated with non-opsonized SRBC is shown (Fig. 5).

The ability to activate the classical pathway of




Fig. 5. Phagocytosis of IgG1- and IgG4-opsonized SRBC by neutrophils. PKH26-labeled SRBC were sensitized with different concentrations of the mAbs and after incubation with neutrophils, phagocytosis was measured by flow cytometry. The solid bar represents the level of background phagocytosis of non-opsonized SRBC.

complement, resulting in lysis of SRBC, was determined for a series of S6 mAb concentrations. The concentration of mAb that gave 50% lysis of SRBC (CH50) was calculated for the four IgG subclasses of S6-Ab (Fig. 6). Induction of hemolysis by IgG1 was very efficient, reaching optimal lysis at approximately 1 μg/ml of mAb. IgG3 also was capable of lysing SRBC, albeit slightly less efficiently than IgG1. IgG4 did not lyse SRBC at concentrations of up to 10 μg/ml, whereas marginal lysis was observed with




Fig. 6. Isotype-dependent, complement-mediated hemolysis. SRBC were sensitized with serially diluted mAb preparations and the amount of human serum required for 50% hemolysis was determined (CH50). As controls, non-opsonized SRBC and SRBC opsonized with serum from a hyperimmunized rabbit (R22) were included.

IgG2 at the highest mAb concentration tested (Fig. 6).

4. Discussion

Phage Ab display technology has facilitated the rapid isolation of human Ab fragments specific for a wide variety of purified antigens, micro-organisms and eukaryotic cells. We have previously described the construction of a semi-synthetic phage Ab display library of scFv fragments and its applications (de Kruif et al., 1995a,b, 1996; Boel et al., 1998). Here we show that scFv selected from this library can be converted to complete and functional human mAbs of each of the eight isotypes. For the V_H region, the procedure was designed to encompass two cloning steps and avoids PCR amplification procedures and concomitant introduction of mutations. In the first step, the V_H region is cloned into the intermediate pLEADER vector to append the HAVT20 leader peptide sequence and a splice donor site. The T cell receptor α chain leader HAVT20 (Kimura et al., 1987) was selected because it allowed the introduction of a *NcoI* restriction site facilitating the subcloning of the V_H chain, without interfering with the amino acid sequence. In addition, the pLEADER vector contains the genomic J_H4 sequence downstream of a *SalI* restriction site to complete the V_H gene and to introduce the genomic splice donor sequence. In the second cloning step, the V_H region with appended leader and splice donor site is subcloned into one of eight expression vectors containing genomic sequences of each of the different human Ig C region genes. The genomic splice acceptor sequence resides in the C region domain constructs, resulting in the removal of the artificial intron between V_H and the C region by splicing.

The HAVT20 leader was also used for the construction of vectors for the expression of Ig L chains. A sequence encoding the first four amino acids of the V_L region, containing a *SacI* restriction site, was used in the phage library to facilitate cloning of V_L genes (de Kruif et al., 1995a). This same sequence was fused in frame to the HAVT20 leader sequence in the pLEADER vector. PCR amplification was used to complete the V_L domain and to introduce the genomic splice donor sequence and a *NotI* restriction

site for cloning (Fig. 1A). A set of seven L chain expression vectors containing each of the L chains used to assemble our phage Ab display library can be repeatedly used for expression of new human mAbs, based on scFv derived from this library.

Ig constructs were introduced in BHK21 cells transfected with the furin gene. Fur-BHK21 cells yield higher amounts of recombinant proteins as compared to BHK21 cells (Lankhof, 1996), probably because fur-BHK21 cells reach higher cell densities at confluency, resulting in increased protein accumulation in the supernatant. In addition, supernatants from fur-BHK21 cells may be harvested up to 8 weeks after reaching confluency. After purification, Ab yields of up to 18 mg/l of culture supernatant were obtained, comparing favorably to published production levels of recombinant human Abs that were not specifically selected for high levels of expression (Brüggemann et al., 1987; Co et al., 1992; Bender et al., 1993; Persic et al., 1997). Of note, IgM and IgE transfectants yielded considerably lower levels of Abs.

N-Terminal amino acid sequence analysis of the V_H3 and V_L3 chains encoding Ab S6-IgG4, showed that the HAVT20 leader peptide was correctly removed from both the H and L chains in the mature Ab. The glycosylation pattern of recombinant mAbs produced in fur-BHK21 cells was analyzed using lectins specific for sugar residues attached in different stages of maturation of the oligosaccharide (reviewed in Wright and Morrison, 1997). MAb in the crude culture supernatant appeared to be completely glycosylated, resulting in oligosaccharides with terminal galactose and sialic acid residues. In contrast, the latter residues could not be detected on purified Abs obtained after protein A chromatography. It is likely that these residues were removed in the elution step with low pH buffers. Thus, fur-BHK-21 cells attach polysaccharides to the Ab molecules which are subsequently trimmed and processed to the complex biantennary form.

The IgG and IgA mAbs produced by fur-BHK21 cells assembled correctly as shown by SDS-PAGE analysis under nonreducing conditions (Fig. 3B). The IgA2m(1) allotype expressed here does not contain disulfide bonds between H and L chains; instead disulfide-bonded L chains dimers are formed (Mestecky and Kilian, 1985), which are linked to the

H chains by noncovalent interactions, explaining the predominant bands of 120 and 50 kDa molecular mass.

The different isotypes of the human Ab S6 bound to Fc receptors in a pattern consistent with published reports (van de Winkel and Anderson, 1991; Shen, 1992). IgG1 and IgG3 interacted with all Fc γ receptors tested, whereas IgG2 was efficiently bound by the Fc γ RIIa-H131 transfectant only. IgG4-sensitized SRBC bound to Fc γ RI-transfected cells, but some rosetting with Fc γ RIIa was also seen. The IgA1 and IgA2 preparations bound to Fc α RI-transfected cells only, and no IgG preparation bound to these cells. Phagocytosis of IgG1- but not of IgG4-opsonized SRBC is consistent with the absence or very low level expression of Fc γ RI on resting neutrophils (Antal-Szalmas et al., 1997).

In our model, IgG1 induced complement-mediated lysis much more efficiently than IgG3. The relative efficiency of lysis of target cells by different Ig subclasses has been shown to be dependent on the target epitope. IgG1 is considerably more effective than IgG3 in mediating lysis of NIP-coated erythrocytes (Brüggemann et al., 1987; Bindon et al., 1988), while IgG3 is more effective at mediating lysis of dansyl-coated erythrocytes (Dangl et al., 1988). However, in another report using NIP-coated erythrocytes, IgG1 was better than IgG3 at high antigen concentration, while the reverse was observed at lower antigen concentration (Garred et al., 1989; Lucisano Valim and Lachmann, 1991). IgG2 was only effective at the highest antigen densities. This observation fits well with the known preferential IgG2 response against polysaccharides on encapsulated bacteria. The repetitive epitopes of polysaccharides would fulfil the requirements for complement activation found in these studies. Indeed, complement activation by the human IgG2 isotype has been reported for purified polyclonal Ab preparations directed against bacteria (Weinberg et al., 1986; Givner et al., 1987; Amir et al., 1990; Bredius et al., 1992). The recombinant S6 Abs recognize a naturally occurring antigen on SRBC, which, in Scatchard analysis, was estimated to be expressed at less than 3000 molecules per cell. Indeed, IgG2 induced some hemolysis only at the highest Ab concentrations tested, while maximum complement-mediated hemolysis was reached at low IgG1 and IgG3

concentrations. As expected, no hemolysis was observed with IgG4 at any of the Ab concentrations tested.

The conversion of phage Abs fragments to complete Ig molecules of a single isotype has been reported for a tetanus toxoid-specific human Fab fragment (Bender et al., 1993), two complement component C5a-specific murine Fab fragments (Ames et al., 1995), a HPA-1a-specific human scFv Ab (Watkins et al., 1999), and a human scFv Ab fragment of which the target was not specified (Persic et al., 1997). The Fab fragments and the HPA-1a-specific scFv fragments performed similarly to the corresponding whole Abs (Bender et al., 1993; Ames et al., 1995; Watkins et al., 1999), whereas the specificity and biological activity of the other scFv fragment and corresponding whole Ab have not been compared (Persic et al., 1997). The SRBC-specific scFv fragment described here was converted to intact fully human anti-SRBC Abs of all eight isotypes. The Abs retained binding specificity, were correctly assembled and glycosylated and performed in Fc receptor binding, complement activation and phagocytosis assays conform their Ig isotype. Human scFv fragments against a wide variety of antigens have been isolated from a number of combinatorial and semi-synthetic phage display libraries. Recently developed mutagenesis and selection strategies facilitate the construction of very high affinity derivatives with affinities in the picomolar range (Schier et al., 1996). The expression vectors described here facilitate the rapid construction of high affinity, intact fully human mAbs for clinical application using scFv Ab fragments selected from phage display libraries as building blocks.

References

- Ames, R.S., Tornetta, M.A., Deen, K., Jones, C.S., Swift, A.M., Ganguly, S., 1995. Conversion of murine Fabs isolated from a combinatorial phage display library to full length immunoglobulins. *J. Immunol. Methods* 184, 177.
- Amir, J., Scott, M.G., Nahm, M.H., Granoff, D.M., 1990. Bactericidal and opsonic activity of IgG1 and IgG2 anticapsular antibodies to *Haemophilus influenzae* type b. *J. Infect. Dis.* 162, 163.
- Antal-Szalmas, P., Van Strijp, J.A.G., Weersink, A.J.L., Verhoef, J., van Kessel, K.P.M., 1997. Quantitation of surface CD14 on human monocytes and neutrophils. *J. Leukocyte Biol.* 61, 721.

- Bender, E., Woof, J.M., Atkin, J.D., Barker, M.D., Bebbington, C.R., Burton, D.R., 1993. Recombinant human antibodies: linkage of an Fab fragment from a combinatorial library to an Fc fragment for expression in mammalian cell culture. *Hum. Antibod. Hybridomas* 4, 74.
- Bindon, C.I., Hale, G., Brüggemann, M., Waldmann, H., 1988. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. *J. Exp. Med.* 168, 127.
- Boel, E., Bootsma, H., de Kruij, J., Jansze, M., Klingman, K.L., van Dijk, H., Logtenberg, T., 1998. Phage antibodies obtained by competitive selection on complement-resistant *Moraxella (Branhamella) catarrhalis* recognize the high-molecular-weight outer membrane protein. *Infect. Immun.* 66, 83.
- Bonnefoy-Berard, N., Revillard, J.P., 1996. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. *J. Heart Lung Transplant* 15, 435.
- Bredius, R.G.M., Driedijk, P.C., Schouten, M.F.J., Weening, R.S., Out, T.A., 1992. Complement activation by polyclonal immunoglobulin G1 and G2 antibodies against *Staphylococcus aureus*, *Haemophilus influenzae* type b and Tetanus toxoid. *Infect. Immun.* 60, 4838.
- Brüggemann, M., Williams, C.T., Bindon, C.I., Clark, M.R., Walker, M.R., Jefferis, R., Waldmann, H., Neuberger, M.S., 1987. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. *J. Exp. Med.* 166, 1351.
- Burton, D.R., Barbas, C.F., 1994. Human antibodies from combinatorial libraries. *Adv. Immunol.* 57, 191.
- Co, M.S., Avdalovic, N.M., Caron, P.C., Avdalovic, M.V., Scheinberg, D.A., Queen, C., 1992. Chimeric and humanized antibodies with specificity for the CD33 antigen. *J. Immunol.* 148, 1149.
- Dangl, J.L., Wensel, T.G., Morrison, S.L., Stryer, L., Herzenberg, L.A., Oi, V.T., 1988. Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies. *EMBO J.* 7, 1989.
- de Kruij, J., Boel, E., Logtenberg, T., 1995a. Selection and application of human single chain Fv antibody fragments from a semi-synthetic phage antibody display library with designed CDR3 regions. *J. Mol. Biol.* 248, 97.
- de Kruij, J., Terstappen, L., Boel, E., Logtenberg, T., 1995b. Rapid selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage antibody library. *Proc. Natl. Acad. Sci. USA* 92, 3938.
- de Kruij, J., van der Vuurst de Vries, A., Cilenti, L., Boel, E., van Ewijk, W., Logtenberg, T., 1996. New perspectives on recombinant human antibodies. *Immunol. Today* 17, 453.
- Garred, P., Michaelsen, T.E., Aase, A., 1989. The IgG subclass pattern of complement activation depends on epitope density and antibody and complement concentration. *Scand. J. Immunol.* 30, 379.
- Givner, L.B., Baker, C.J., Edwards, M.S., 1987. Type III group B *Streptococcus*: functional interaction with IgG subclass antibodies. *J. Infect. Dis.* 155, 532.
- Graham, F., van der Eb, A., 1973. A new technique for the assay of infectivity of human adenovirus 5 DNA. *Virology* 52, 456.
- Hieter, P.A., Maizel, J.V., Leder, P., 1982. Evolution of human immunoglobulin kappa J region genes. *J. Biol. Chem.* 257, 1516.
- Hoogenboom, H.R., Griffiths, A.D., Johnson, K.S., Chiswell, D.J., Hudson, P., Winter, G., 1991. Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. *Nucl. Acids Res.* 19, 4133.
- Jaffers, G.J., Fullers, T.C., Cosimi, P.S., Russel, P.S., Winn, H.J., Colvin, R.B., 1986. Monoclonal antibody therapy. Anti-idiotypic and non-anti-idiotypic antibodies to OKT3 arising despite intense immunosuppression. *Transplantation* 41, 572.
- Jones, P.T., Dear, P.H., Foote, J., Neuberger, M.S., Winter, G., 1986. Replacing the complementarity-determining regions in a human antibody with those from a mouse. *Nature* 321, 522.
- Kabat, E.A., Wu, T.T., Oerry, H.M., Gottesman, K.S., Foeller, C., 1991. Sequences of proteins of immunological interest. US Department of Health and Human Services, Public Health Service, National Institutes of Health, Bethesda, MD.
- Kimura, N., Toyonaga, B., Yoshikai, Y., Du, R., Mak, T.W., 1987. Sequences and repertoire of the human T cell receptor α and β chain variable region genes in thymocytes. *Eur. J. Immunol.* 17, 375.
- Kirsch, I.R., Morton, C.C., Nakahara, K., Leder, P., 1982. Human immunoglobulin heavy chain genes map to a region of translocation in malignant B lymphocytes. *Science* 216, 301.
- Klerx, J.P.A.M., Beukelman, C.J., van Dijk, H., Willers, J.M.N., 1983. Microassay for colorimetric estimation of complement activity in guinea pig, human and mouse serum. *J. Immunol. Methods* 63, 215.
- Lankhof, H., 1996. Ph.D. Thesis, University of Utrecht, Utrecht, The Netherlands.
- Lucisano Valim, Y.M., Lachmann, P.J., 1991. The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions. *Clin. Exp. Immunol.* 84, 1.
- Marks, J.D., Hoogenboom, H.R., Bonnert, T.P., McCafferty, J., Griffiths, A.D., Winter, G., 1991. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. *J. Mol. Biol.* 222, 581.
- Max, E.E., Battey, J., Ney, R., Kirsch, I.R., Leder, P., 1982. Duplication and deletion in the human immunoglobulin epsilon genes. *Cell* 29, 691.
- Mendez, M.J., Green, L.L., Corvalan, J.R.E., Jia, X., Maynard-Currie, C.E., Yang, X., Gallo, M.L., Louie, D.M., Lee, D.V., Erickson, K.L., Luna, J., Roy, C.M.-N., Abderrahim, H., Kirschenbaum, F., Noguchi, M., Smith, D.H., Fukushima, A., Hales, J.F., Finer, M.H., Davis, C.G., Zsebo, K.M., Jakobovits, A., 1997. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. *Nat. Genet.* 15, 146.
- Mestecky, J., Kilian, M., 1985. Immunoglobulin A (IgA). *Methods Enzymol.* 116, 37.
- Morrison, S.L., Johnson, M.J., Herzenberg, L.A., Oi, V.T., 1984. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. *Proc. Natl. Acad. Sci. USA* 81, 6851.
- Morton, H.C., Atkin, J.D., Owens, R.J., Woof, J.M., 1993.

- Purification and characterization of chimeric human IgA1 and IgA2 expressed in COS and chinese hamster ovary cells. *J. Immunol.* 151, 4743.
- Morton, H.C., van den Herik-Oudijk, I.E., Vossebeld, P., Snijders, A., Verhoeven, A.J., Capel, P.J.A., van de Winkel, J.G.J., 1995. Functional association between the human myeloid immunoglobulin A Fc receptor (CD89) and FcR gamma chain. Molecular basis for CD89/FcR gamma chain association. *J. Biol. Chem.* 270, 29781.
- Ory, P.A., Clark, M.R., Talhouk, A.S., Goldstein, I.M., 1991. Transfected NA1 and NA2 forms of human neutrophil Fc receptor III exhibit antigenic and structural heterogeneity. *Blood* 77, 2682.
- Palmiter, R.D., Behringer, R.R., Quaife, C.J., Maxwell, F., Maxwell, I.H., Brinster, R.L., 1987. Cell lineage ablation in transgenic mice by cell-specific expression of a toxin gene. *Cell* 50, 435.
- Persic, L., Robert, A., Wilton, J., Cattaneo, A., Bradbury, A., Hoogenboom, H.R., 1997. An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries. *Gene* 187, 9.
- Ravetch, J.V., Kirsch, I.R., Leder, P., 1980. Evolutionary approach to the question of immunoglobulin heavy chain switching: Evidence from cloned human and mouse genes. *Proc. Natl. Acad. Sci. USA* 77, 6734.
- Sasano, M., Burton, D.R., Silverman, G.J., 1993. Molecular selection of human antibodies with an unconventional bacterial B cell antigen. *J. Immunol.* 151, 5822.
- Schier, R., McCall, A., Adams, G.P., Marshall, K.W., Merritt, H., Yim, M., Crawford, R.S., Weiner, L.M., Marks, C., Marks, J.D., 1996. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. *J. Mol. Biol.* 263, 551.
- Shen, L., 1992. Receptors for IgA on phagocytic cells. *Immunol. Res.* 11, 273.
- Taylor, L.D., Carmack, C.E., Schramm, S.R., Mashayekh, R., Higgins, K.M., Kuo, C.-C., Woodhouse, C., Kay, R.M., Lonberg, N., 1992. A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins. *Nucl. Acids Res.* 20, 6287.
- Troelstra, A., Giepmans, B.N.G., van Kessel, K.P.M., Lichtenstein, H.S., Verhoef, J., Van Strijp, J.A.G., 1997. Dual effects of soluble CD14 on LPS priming of neutrophils. *J. Leukocyte Biol.* 61, 173.
- Van Amersfoort, E.S., Van Strijp, J.A.G., 1994. Evaluation of a flow cytometric fluorescence quenching assay of phagocytosis of sensitized sheep erythrocytes by polymorphonuclear leukocytes. *Cytometry* 17, 294.
- van de Winkel, J.G.J., Anderson, C.L., 1991. Biology of human immunoglobulin G Fc receptors. *J. Leukocyte Biol.* 49, 511.
- van de Winkel, J.G.J., Tax, W.J.M., van Bruggen, M.C.J., Roozendaal, C.E.P., Willems, H.W., Vlug, A., Capel, P.J.A., Koene, R.A.P., 1987. Characterization of two Fc receptors for mouse immunoglobulins on human monocytes and cell lines. *Scand. J. Immunol.* 26, 663.
- van den Herik-Oudijk, I.E., Westerdaal, N.A.C., Henriquez, N.V., Capel, P.J.A., van de Winkel, J.G.J., 1994. Functional analysis of human Fc gamma RII (CD32) isoforms expressed in B lymphocytes. *J. Immunol.* 152, 574.
- van der Stoep, N., 1995. Ph.D. Thesis, University of Utrecht, Utrecht, The Netherlands.
- van Vugt, M.J., Heijnen, A.F., Capel, P.J.A., Park, S.Y., Ra, C., Saito, T., Verbeek, J.S., van de Winkel, J.G.J., 1996. FcR gamma-chain is essential for both surface expression and function of human Fc gamma RI (CD64) in vivo. *Blood* 87, 3593.
- Watkins, N.A., Armour, K.L., Smethurst, P.A., Metcalfe, P., Scott, M.L., Hughes, D.L., Smith, G.A., Williamson, L.M., Clark, M.R., Ouwehand, W.H., 1999. Rapid phenotyping of HPA-1a using either diabody-based hemagglutination or recombinant IgG1-based assays. *Transfusion* 39, 781.
- Weinberg, G.A., Granoff, D.M., Nahm, M.H., Shackelford, P.G., 1986. Functional activity of different IgG subclass antibodies against type b capsular polysaccharide of *Haemophilus influenzae*. *J. Immunol.* 136, 4232.
- Winter, G., Griffiths, A.D., Hawkins, R.E., Hoogenboom, H.R., 1994. Making antibodies by phage display technology. *Annu. Rev. Immunol.* 12, 433.
- Wright, A., Morrison, S.L., 1997. Effect of glycosylation on antibody function: implications for genetic engineering. *Trends Biotechnol.* 15, 26.